Q-omics provides the consensus-scored DENND5B profile across patient tissues and cancer cell-line models. DENND5B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DENND5B is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, DENND5B RNA expression shows 20,750 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where DENND5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND5B survival associations across molecular data types. DENND5B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND5B RNA expression–survival associations across cancer types. High DENND5B expression shows unfavorable associations in LUSC and MESO, but favorable associations in KIRC, OV, BRCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DENND5B RNA expression.
This table summarizes DENND5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DENND5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND5B shows lower tumor expression in COAD, BLCA, BRCA and THCA and higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher DENND5B RNA expression in tumor versus normal tissue (log2 FC = +0.645, t-test p < 0.001).
This table shows molecular features associated with DENND5B in patient tissues and cancer cell lines. In patient samples, DENND5B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
